Clinical Trials Logo

Clinical Trial Summary

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.


Clinical Trial Description

A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects with HER2 Overexpressing Solid Tumors Main Study - Group 1 and Group 2 all HER2 overexpressing solid tumors Intraperitoneal Substudy - HER2 overexpressing peritoneal disease 89[Zr] radiolabeled CT-0508 Substudy - All HER2 overexpressing solid tumors (Univ of Penn, Abramson Cancer Center only) CT-0508 Combination with Pembrolizumab Substudy - All HER2 overexpressing solid tumors ;


Study Design


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Bile Duct Cancer
  • Bile Duct Neoplasms
  • Biliary Tract Cancer
  • Biliary Tract Neoplasms
  • Bladder Cancer
  • Breast Cancer
  • Breast Neoplasm
  • Breast Neoplasms
  • Cancer
  • Carcinoma
  • Carcinoma, Ductal
  • Carcinoma, Hepatocellular
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Ovarian Epithelial
  • Carcinoma, Small Cell
  • Carcinoma, Squamous
  • Carcinoma, Squamous Cell
  • Carcinoma, Transitional Cell
  • Colorectal Cancer
  • Endometrial Cancer
  • Endometrial Neoplasms
  • Esophagogastric Junction Neoplasms
  • Head and Neck Cancer
  • Head and Neck Neoplasms
  • HER-2 Gene Amplification
  • HER-2 Protein Overexpression
  • HER2-positive
  • HER2-positive Breast Cancer
  • HER2-positive Gastric Cancer
  • HER2-positive Solid Tumors
  • Inflammatory Breast Cancer
  • Lung Cancer, Small Cell
  • Lung Neoplasms
  • Malignant Neoplasms
  • Neoplasms
  • Ovarian Neoplasms
  • Pancreatic Cancer
  • Prostate Cancer
  • Prostatic Neoplasms
  • Small Cell Lung Carcinoma
  • Stomach Neoplasms

NCT number NCT04660929
Study type Interventional
Source Carisma Therapeutics Inc
Contact
Status Active, not recruiting
Phase Phase 1
Start date February 2, 2021
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A